Natco Pharma (NATCOPHARM)
FAST GROWERFairStock Score: 80/100 — HIGH CONVICTION
Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 1/2 · Dividend: 0/1
Key Financials
| Current Price | ₹1,071.45 |
| Market Cap | ₹17,705.01 Cr |
| P/E Ratio | 11.37 |
| ROCE | 32.78% |
| ROE | 20.47% |
| Dividend Yield | 0.61% |
| Profit Growth | -16.51% |
| Debt/Equity | 0.03 |
| Sales Growth | 6.63% |
| Free Cash Flow | ₹26,100 Cr |
| Promoter Holding | 49.48% |
| 52-Week Range | ₹789 — ₹1,224.1 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹424.71 |
Natco Pharma trades with a P/E ratio of 11.37, ROCE of 32.78%, ROE of 20.47%, profit growth of -16.51%, debt-to-equity of 0.03. The FairStock Score of 80/100 reflects strong fundamentals across multiple dimensions.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer